Research Papers

21 of 21 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
Perera SD; Hegele RA.
Curr Opin Lipidol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Angiopoietin-like 3 inhibition and the liver: less is more?
Oostveen RF; Hovingh GK; Stroes ESG.
Curr Opin Lipidol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The pathophysiology of excess plasma-free cholesterol.
Gillard BK; Rosales C; Gotto AM; Pownall HJ.
Curr Opin Lipidol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Vascular stiffening and endothelial dysfunction in atherosclerosis.
Hooglugt A; Klatt O; Huveneers S.
Curr Opin Lipidol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
New algorithms for treating homozygous familial hypercholesterolemia.
Tromp TR; Cuchel M.
Curr Opin Lipidol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis of atherosclerosis.
Kim K; Park SE; Park JS; Choi JH.
Curr Opin Lipidol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Considerations for routinely testing for high lipoprotein(a).
Nurmohamed NS; Moriarty PM; Stroes ES.
Curr Opin Lipidol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Very long-chain saturated fatty acids and diabetes and cardiovascular disease.
Lemaitre RN; King IB.
Curr Opin Lipidol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
ANGPTL3 as therapeutic target.
Kersten S.
Curr Opin Lipidol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case.
Wand H; Knowles JW; Clarke SL.
Curr Opin Lipidol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease.
Liao F; Yoon H; Kim J.
Curr Opin Lipidol (Unknown)
Published: 2017
2/6 Transparent
Funding Declared
Milk fat biomarkers and cardiometabolic disease.
Risérus U; Marklund M.
Curr Opin Lipidol (Unknown)
Published: 2017
2/6 Transparent
Funding Declared
Cardiovascular diseases in mega-countries: the challenges of the nutrition, physical activity and epidemiologic transit…
Barquera S; Pedroza-Tobias A; Medina C.
Curr Opin Lipidol (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Effects of melatonin on cardiovascular diseases: progress in the past year.
Sun H; Gusdon AM; Qu S.
Curr Opin Lipidol (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
LDL-cholesterol transport to the endoplasmic reticulum: current concepts.
Pfisterer SG; Peränen J; Ikonen E.
Curr Opin Lipidol (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.
Chapman MJ; Stock JK; Ginsberg HN; PCSK9 Forum.
Curr Opin Lipidol (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis.
Huber HJ; Holvoet P.
Curr Opin Lipidol (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia.
Pears R; Griffin M; Futema M; Humphries SE.
Curr Opin Lipidol (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability.
Hutcheson JD; Maldonado N; Aikawa E.
Curr Opin Lipidol (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.
Lagace TA.
Curr Opin Lipidol (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase a…
Filippov S; Pinkosky SL; Newton RS.
Curr Opin Lipidol (Unknown)
Published: 2014
1/6 Transparent